Kenvue Inc. (NYSE:KVUE) Holdings Lowered by MassMutual Private Wealth & Trust FSB

MassMutual Private Wealth & Trust FSB reduced its holdings in Kenvue Inc. (NYSE:KVUE) by 29.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,892 shares of the company’s stock after selling 2,508 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in Kenvue were worth $126,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in KVUE. Grove Bank & Trust raised its holdings in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares in the last quarter. Riverview Trust Co bought a new stake in shares of Kenvue in the 3rd quarter worth approximately $30,000. Fortitude Family Office LLC raised its holdings in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of Kenvue in the 3rd quarter worth approximately $35,000. Finally, Versant Capital Management Inc raised its holdings in shares of Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after purchasing an additional 1,441 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

Shares of KVUE opened at $20.75 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $39.77 billion, a PE ratio of 37.72, a PEG ratio of 2.00 and a beta of 1.46. The company’s 50 day moving average price is $22.26 and its 200 day moving average price is $21.74. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company’s revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.31 earnings per share. Research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.95%. The ex-dividend date is Wednesday, February 12th. Kenvue’s payout ratio is 149.09%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on KVUE shares. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and dropped their target price for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Royal Bank of Canada raised shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. JPMorgan Chase & Co. lifted their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. UBS Group dropped their target price on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research report on Thursday, January 16th. Finally, Citigroup dropped their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.08.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.